<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434209</url>
  </required_header>
  <id_info>
    <org_study_id>LAPIS</org_study_id>
    <nct_id>NCT04434209</nct_id>
  </id_info>
  <brief_title>A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)</brief_title>
  <acronym>LAPIS</acronym>
  <official_title>Limiting AKI Progression In Sepsis (LAPIS): A Phase 4, Multicenter, Randomized Controlled Trial of Biomarker-guided Delivery of Kidney-sparing Care Measures in Sepsis Subjects at Risk of Developing AKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMérieux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biomarkers that provide an early indicator of kidney stress could be useful in clinical&#xD;
      practice to detect silent episodes of acute kidney injury (AKI) or for early identification&#xD;
      of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators&#xD;
      of AKI. The NephroCheck® test is a commercially available test that uses these biomarkers,&#xD;
      and this study assesses the use of these in reducing negative clinical outcomes for patients&#xD;
      with sepsis-associated AKI. The study will enroll subjects diagnosed with sepsis, including&#xD;
      septic shock, who will be randomly assigned to either receive NephroCheck®-guided&#xD;
      kidney-sparing and fast-tracking interventions; or to receive current Standard of Care&#xD;
      assessment and treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of deaths, dialysis or progression of AKI</measure>
    <time_frame>Enrollment to 72 hours</time_frame>
    <description>Measured by composite number of deaths, dialysis or progression of AKI. Dialysis defined as any form of renal replacement therapy (RRT); progression of AKI defined as Stage 0 to 2/3 or Stage 1 to 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with progression of AKI</measure>
    <time_frame>Enrollment to 24, 48 and 72 hours</time_frame>
    <description>Progression of 2 or more stages of AKI (Stage 0 to 2/3 or Stage 1 to 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>Enrollment to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants receiving dialysis</measure>
    <time_frame>Enrollment to 72 hours</time_frame>
    <description>Dialysis defined as any form of renal replacement therapy (RRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants progressing from Stage 2 to 3 of AKI</measure>
    <time_frame>Enrollment to 24 and 48 hours</time_frame>
    <description>Defined as highest stage of AKI during the time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants progressing from Stage 1 to Stage 2 of AKI</measure>
    <time_frame>Enrollment to 24, 48 and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths, dialysis or progression of AKI (Acute Kidney Injury)</measure>
    <time_frame>Enrollment to 24 and 48 hours</time_frame>
    <description>Dialysis defined as any form of renal replacement therapy (RRT); progression of AKI defined as Stage 0 to 2/3 or Stage 1 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with renal recovery</measure>
    <time_frame>Enrollment to hospital discharge or Day 60, whichever is sooner</time_frame>
    <description>Defined as &lt;120% Study Reference creatinine level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU-free (Intensive Care Unit) days</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RRT-free (Renal Replacement Therapy) days</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AKI Stage 2/3-free days</measure>
    <time_frame>Enrollment to hospital discharge or Day 60, whichever is sooner</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death, dialysis or progression of AKI</measure>
    <time_frame>Enrollment to 72 hours</time_frame>
    <description>Progression of AKI defined as progression of 2 or more stages (Stage 0 to 2/3 or Stage 1 to 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Enrollment to hospital discharge or Day 60, whichever is sooner</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to renal recovery</measure>
    <time_frame>Enrollment to hospital discharge or Day 60, whichever is sooner</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Sepsis</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>NephroCheck-guided interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care assessment and treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subject management guided by NephroCheck® test</intervention_name>
    <description>NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury</description>
    <arm_group_label>NephroCheck-guided interventions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care patient management</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of sepsis or septic shock.&#xD;
&#xD;
          -  Admission to the ICU or planned admission to the ICU with an expected stay of 72 hours&#xD;
             or more after enrollment in the same hospital.&#xD;
&#xD;
          -  Expected to have indwelling urinary catheter placed and kept until at least 48 hours&#xD;
             after enrollment.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with known pregnancy, prisoners or institutionalized individuals.&#xD;
&#xD;
          -  Previous renal transplant.&#xD;
&#xD;
          -  Stage 2 or 3 Acute Kidney Injury (AKI) at screening.&#xD;
&#xD;
          -  Receiving dialysis (either acute or chronic), or in imminent need of dialysis at&#xD;
             enrollment.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 45 mL/min/1.73 m2.&#xD;
&#xD;
          -  Known End Stage Renal Disease (ESRD) or history of active nephrotic syndrome within&#xD;
             the last 3 months.&#xD;
&#xD;
          -  Known Stage 2-3 AKI within last 2 weeks.&#xD;
&#xD;
          -  Terminally ill (defined as expectation of death within 6 months), has a do not&#xD;
             resuscitate order that would restrict protocol-required procedures, or is being&#xD;
             admitted only for palliative care.&#xD;
&#xD;
          -  History of solid organ transplant and receiving calcineurin inhibitors.&#xD;
&#xD;
          -  Documented serious allergy (i.e. anaphylaxis) to vancomycin, aminoglycosides,&#xD;
             penicillins, or cephalosporins (intravenous or oral).&#xD;
&#xD;
          -  Known current serum total bilirubin &gt; 4mg/dL.&#xD;
&#xD;
          -  Subjects already included in an observational study can be co-enrolled in LAPIS.&#xD;
             Subjects already included in an interventional study may be enrolled with pre-approval&#xD;
             of the sponsor according to the following rules:&#xD;
&#xD;
               1. Co-enrollment in LAPIS will not be allowed with investigational drug and device&#xD;
                  studies;&#xD;
&#xD;
               2. Studies may be allowed if AKI or kidney function is not an endpoint with&#xD;
                  pre-approval of the LAPIS sponsor;&#xD;
&#xD;
               3. Co-enrollment in LAPIS will not be allowed if co-enrollment is an exclusion&#xD;
                  criterion in the other study.&#xD;
&#xD;
          -  Subjects with laboratory confirmed COVID-19 infection as the primary reason for&#xD;
             hospital admission.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hernando Gomez, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Critical Care Nephrology, University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabienne Heskia</last_name>
    <phone>+33 478 877 392</phone>
    <email>fabienne.heskia@biomerieux.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LSU Health Sciences Center, 1541 Kings Highway</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital, 75 Francis Street</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center, 1275 York Avenue</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende, Intensieve Zorgen, Ruddershove 10</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme, Soins Intensifs, Route de Lennik 808</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers, 4 Rue Larrey</name>
      <address>
        <city>Angers</city>
        <state>Maine-et-Loire</state>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Béthune, Service de Réanimation et Surveillance continue, 27 rue Delbecque</name>
      <address>
        <city>Béthune</city>
        <state>Pas-de-Calais</state>
        <zip>62408</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Dijon Complexe Du Bocage, Department Infectiologie, 14 rue Gaffarel</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin, 27 Rue Du Faubourg Saint Jacques</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg, Klinik für Anaesthesiologie, Im Neuenheimer Feld 110</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig, Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Liebigstraße 20</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster, Albert-Schweitzer-Campus 1</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>Kidney damage</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

